Lymph node Biopsy - XL

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Biopsy of lymph node tissue.

₹888₹1,269

30% OFF

Lymph Node Biopsy - XL: Comprehensive Medical Test Information Guide

Why is it done?
- Test Description: A lymph node biopsy-XL is a surgical procedure that involves the removal and microscopic examination of lymph node tissue. The 'XL' designation typically indicates an extended or comprehensive analysis including histopathology, immunohistochemistry, and flow cytometry analysis performed on a larger specimen.
- Primary Indications: Diagnosis of lymphoma (Hodgkin and non-Hodgkin lymphomas); evaluation of persistent lymphadenopathy (enlarged lymph nodes); diagnosis of leukemia or other hematologic malignancies; detection of metastatic cancer; diagnosis of infectious diseases affecting lymph nodes; evaluation of autoimmune or inflammatory conditions; characterization of immunodeficiency disorders.
- When is it Performed: When lymph nodes remain enlarged (>1 cm) for more than 4-6 weeks; when imaging studies (CT, PET) show abnormal lymph nodes; when patients present with constitutional symptoms (fever, night sweats, weight loss) and lymphadenopathy; during cancer staging or restaging; when initial diagnostic tests are inconclusive; when immunophenotyping or genetic analysis is needed for optimal diagnosis and treatment planning.
Normal Range
- Normal Findings: Benign, reactive lymph node tissue with normal architecture; appropriate distribution of lymphocytes, histiocytes, and germinal centers; absence of malignant cells; normal follicular hyperplasia (if reactive to infection or immunologic stimulation); maintained nodal architecture with intact lymph follicles.
- Interpretation of Results: Negative/Normal = benign reactive process, no evidence of malignancy, infection diagnosed (if infectious etiology identified); Positive = malignancy detected (lymphoma type specified), metastatic disease present, specific infectious agent identified, or immunologic abnormality documented.
- Units of Measurement: Qualitative histopathologic diagnosis; immunophenotype percentages; cytogenetic findings reported as presence/absence of abnormalities; flow cytometry results as percentage of abnormal cell populations.
- Normal vs Abnormal: Normal indicates absence of malignancy and preserved lymph node architecture appropriate for age and clinical context; Abnormal indicates presence of neoplastic cells, architectural distortion, infectious agents, or immunologic abnormalities requiring clinical correlation and further management.
Interpretation
- Benign/Reactive Findings: Reactive hyperplasia (follicular hyperplasia, paracortical hyperplasia); infection-related changes; normal germinal center reactions; benign proliferative conditions; typically associated with infectious processes, autoimmune diseases, or previous vaccination.
- Malignant Findings: Hodgkin lymphoma (classical or nodular lymphocyte-predominant); non-Hodgkin lymphoma subtypes (B-cell lymphomas, T-cell lymphomas, Burkitt lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, etc.); metastatic carcinoma; leukemic infiltration; myeloma involvement; requires detailed classification, staging, and prognostic marker assessment.
- Infectious Findings: Bacterial infections (tuberculosis, cat-scratch disease); fungal infections (histoplasmosis, coccidioidomycosis); viral infections (CMV, EBV); parasitic infections; granulomatous inflammation; specific organisms may be identified by special stains or cultures.
- Factors Affecting Results: Specimen adequacy and tissue quality; proper fixation and handling; timing of biopsy relative to treatment; presence of crush artifact or necrosis; interfering medications or recent chemotherapy; immunosuppression status; background normal tissue obscuring abnormal population.
- Clinical Significance: Definitive diagnosis of lymphoid malignancies; determination of lymphoma subtype essential for prognostic stratification and treatment selection; identification of prognostic markers (Ki-67 index, cytogenetics, mutations); assessment of treatment response; detection of Richter transformation; identification of secondary malignancies; critical for clinical decision-making and patient counseling.
Associated Organs
- Primary Organ Systems: Lymphatic system (primary); hematopoietic system; immune system; secondary involvement of multiple organ systems possible including bone, liver, spleen, lungs, GI tract, CNS depending on underlying pathology.
- Associated Diseases: Hodgkin lymphoma; non-Hodgkin lymphomas; chronic lymphocytic leukemia (CLL); acute leukemias; multiple myeloma; metastatic malignancies; tuberculosis; fungal infections; viral infections (EBV, CMV, HIV-related lymphadenopathy); autoimmune conditions (systemic lupus erythematosus, rheumatoid arthritis); sarcoidosis; histiocytosis; immunodeficiency syndromes.
- Diagnostic Capabilities: Definitive diagnosis of hematologic malignancies; disease classification and staging; prognostic stratification; treatment selection; detection of treatment-emergent mutations; identification of clonal populations; assessment of minimal residual disease; diagnosis of infiltrative diseases; characterization of immune dysregulation.
- Potential Complications of Abnormal Results: Diagnosis of malignancy with need for chemotherapy/radiation therapy and associated toxicities; disease progression if untreated; secondary malignancies; transformation to more aggressive disease (Richter transformation in CLL); organ infiltration with functional compromise; infectious complications from immunosuppression; need for intensive monitoring and potential palliative care management.
Follow-up Tests
- Immediate Follow-up Investigations: Staging CT scans (chest, abdomen, pelvis); PET-CT for metabolic assessment; bone marrow biopsy for lymphoma staging and prognostic assessment; lumbar puncture and CNS imaging if CNS involvement suspected; additional biopsies of involved organs.
- Laboratory Tests Based on Diagnosis: Complete blood count (CBC); comprehensive metabolic panel; lactate dehydrogenase (LDH); tumor markers specific to lymphoma type; flow cytometry of peripheral blood and bone marrow; cytogenetic analysis; molecular testing (t(14;18), t(9;22), BCR-ABL mutation analysis); immunoglobulin/free light chain assessment; HIV/Hepatitis serology if clinically indicated.
- Monitoring During Treatment: Repeat imaging every 2-3 cycles of chemotherapy; interim PET-CT assessment (after 2-3 cycles); end-of-treatment imaging; complete blood counts during chemotherapy; metabolic panels to assess organ function; repeat bone marrow biopsy if clinically indicated; minimal residual disease (MRD) testing using flow cytometry or PCR.
- Surveillance After Treatment Completion: Clinical evaluation every 2-4 weeks initially, then every 2-3 months; imaging every 3-4 months for first 1-2 years then as clinically indicated; CBC and metabolic panel every 3 months for first year; PET-CT based on clinical suspicion of recurrence; reinitiation of biopsy if clinical or imaging findings suggest relapse.
- Complementary Tests: Repeat lymph node biopsy for morphologic assessment; repeat immunophenotyping; cytogenetic reassessment; mutation analysis; additional biopsies if diagnosis remains uncertain; consultation with hematopathology for complex cases.
Fasting Required?
- Fasting Status: No fasting required specifically for the biopsy procedure itself.
- Pre-Procedure Preparation: NPO (nothing by mouth) for 6-8 hours if general or moderate sedation will be used; light meal allowed if only local anesthesia planned; clear liquids up to 2-4 hours before procedure if sedation anticipated.
- Medications to Avoid: Anticoagulants (warfarin, apixaban, rivaroxaban) typically held 3-5 days before biopsy; antiplatelet agents (aspirin, clopidogrel) held 5-7 days before procedure; NSAIDs held 48-72 hours prior; herbal supplements with anticoagulant properties (ginkgo, garlic, ginger) held 1-2 weeks; discuss all medications with procedure team for individualized instructions.
- Other Preparation Requirements: Complete pre-operative laboratory testing (CBC, coagulation studies, metabolic panel); obtain informed consent explaining risks and benefits; arrange transportation as driving is not permitted after sedation; wear comfortable, loose-fitting clothing; remove jewelry and valuables; arrange for post-procedure supervision; have someone available for ride home; discuss contrast reactions if imaging required; update allergy history; discontinue contact lenses if facial procedure.
- Post-Procedure Instructions: Resume normal diet when alert; resume anticoagulant/antiplatelet medications as directed by physician (typically 24-48 hours post-biopsy); avoid strenuous activity for 48 hours; keep biopsy site clean and dry; monitor for signs of infection or excessive bleeding; expect some mild pain, swelling, or bruising at biopsy site; take prescribed pain medication as needed; apply ice packs if indicated; follow post-operative wound care instructions.

How our test process works!